On October 13, 2026, Galderma announced new global research showing that more than half (56%) of women first attributed menopause-related skin changes to general aging, while fewer than a third (29%) initially linked them to menopause.
Related: Menopause Goes Mainstream: A New Era of Aesthetic and Hormone Care
The phenomenon is called ‘The Menopausal Skin Misread’, which mistakes menopausal skin changes for aging.
According to the press release, the misread is also influencing skincare purchases: 70% have bought products designed to address signs of ageing because they believed they would help with skin changes experienced during perimenopause or menopause.
Galderma, which also released new clinical data revealing an evidence-based approach for managing menopause-related skin changes, has positioned itself to help bridge this gap.
The eight-month investigator-initiated trial (IIT) conducted by Dr. Andreas Nikolis, demonstrated that the combination of Restylane Skinboosters and Sculptra delivered sustained improvements in skin hydration, quality, remodeling, as well as patient satisfaction in menopausal women.
The research was conducted by Perspectus Global among a sample of 5,090 women who have experienced or are experiencing perimenopause or menopause across the UK, US, Brazil and China. The data was collected between 25 August and 1 September 2026.
“This first-of-its-kind clinical study provides ompelling evidence that sequencing treatments can deliver significantly greater benefits than either approach alone in menopausal skin.," said Dr. Andreas Nikolis in the press release.
With the new data, practitioners now have an evidence-based approach for managing menopause-related skin changes,
